Find updates on preliminary achievements, scientific breakthroughs, clinical trials, number of patients treated, number of investors joining in the initiative, and the amount of money raised. And as the initiative gains momentum, we'll also publish interviews with researchers and doctors, and update you on the web of collaborative efforts surrounding MY ANSWER TO CANCER.
Read our Spring 2013 newsletter (PDF).
Nov. 5, 2012: We are enormously pleased to announce that Razelle Kurzrock, MD, will join the faculty of the Hematology-Oncology Division of the UC San Diego Department of Medicine and the Moores Cancer Center (MCC). Dr. Kurzrock will join the leadership of the Cancer Center as Senior Deputy Director for Clinical Science, bringing unparalleled translational expertise in experimental therapeutics and phase I trials. Among other roles, she will head the MCC Clinical Trials Office and a newly established Center for Personalized Therapy and will serve as Vice Chief for Hematology-Oncology. She joins us after serving as founding chair of the MD Anderson Cancer Center Department of Investigational Cancer Therapeutics, where she developed one of the largest and best early-phase clinical cancer drug development programs in the world. A physician-scientist, Dr. Kurzrock brings extraordinary expertise and experience in clinical research, business operations, regulatory operations, financial and budget planning, and administrative oversight, in addition to her world-recognized work in translational science, PK/PD/blood sampling/processing, and molecular profiling. A dedicated educator, Dr. Kurzrock created and directed two unique training programs in clinical sciences—the MS/PhD program in Patient-based Biological Research (Graduate School of Biomedical Sciences, University of Texas Health Science Center) and the Investigational Cancer Therapeutics Clinical Trials Research Fellowship Program. Dr. Kurzrock also mentored and developed young faculty in her department into world-recognized builders of clinical and translational trials programs.
Dr. Kurzrock has over 400 peer-reviewed publications and a uniquely strong record of competitive grant funding within the setting of phase I program building. She has been the PI of the NCI U01 Phase I Studies of Targeted Anti-Cancer Agents and has served as the MD Anderson PI of the University of Texas Clinical and Translational Science Award. Her standards-changing clinical impact has been driven by science, with several drugs transitioning directly from phase I to phase III development (no intervening phase II step) and some of these drugs now nearing FDA approval. Dr. Kurzrock's group has achieved the unique advance of successfully incorporating advanced molecular profiling technology as a routine procedure for patients involved in early drug development trials, thus making personalized medicine a reality in this setting. Her umbrella protocol for this work is called Profile-related Evidence Determining Individualized Cancer Therapy (PREDICT), which uses molecular technology to understand response and resistance and to match patients to targeted agents based on actionable aberrations. PREDICT has demonstrated that molecular matching of patients with targeted drugs is associated with significantly higher response rates even in the early clinical trials setting where patients with advanced refractory cancer are enrolled.